SLC5A2 and chronic kidney disease: Additionally, SGLT2 inhibitors have been reported to reduce body weight and blood pressure, risk factors for the progression of ADPKD, in non-diabetic patients with CKD [10] and also in those with heart failure [12], while in vivo results have shown increased endogenous ketone body levels [13].